Literature DB >> 17027655

Standard treatment of advanced-stage diffuse large B-cell lymphoma.

Bertrand Coiffier1.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma and is not localized in 70% of the cases. Even if the clinical picture, the morphologic aspect, and the prognostic parameters are different from one patient to another, the standard treatment is the same for all patients. Currently, treatment decision is based on the International Prognostic Index (IPI) and age of the patient. Outcome has been completely modified with the introduction of rituximab in combination with chemotherapy. A review of standard treatment and remaining questions is presented.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17027655     DOI： 10.1053/j.seminhematol.2006.07.004

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  6 in total

1.  High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma.

Authors:  Qi-chun Cai; Hong Liao; Su-xia Lin; Yi Xia; Xiao-xaio Wang; Yan Gao; Ze-xiao Lin; Jia-bin Lu; Hui-qiang Huang
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

2.  Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Robert Griffiths; Michelle Gleeson; Kevin Knopf; Mark Danese
Journal:  BMC Cancer       Date:  2010-11-12       Impact factor: 4.430

Review 3.  Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.

Authors:  Carlo Visco; Silvia Finotto
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

4.  Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.

Authors:  Liat Binyamin; R Katherine Alpaugh; Tracey L Hughes; Charles T Lutz; Kerry S Campbell; Louis M Weiner
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

5.  Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.

Authors:  Isabelle Ray-Coquard; Claire Cropet; Martine Van Glabbeke; Catherine Sebban; Axel Le Cesne; Ian Judson; Olivier Tredan; Jaap Verweij; Pierre Biron; Inthidar Labidi; Jean-Paul Guastalla; Thomas Bachelot; David Perol; Sylvie Chabaud; Pancras C W Hogendoorn; Philippe Cassier; Armelle Dufresne; Jean-Yves Blay
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

6.  Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy.

Authors:  Giovanni Galati; Lorenzo Rampa; Umberto Vespasiani-Gentilucci; Mirella Marino; Francesco Pisani; Carlo Cota; Alessandro Guidi; Antonio Picardi
Journal:  World J Hepatol       Date:  2016-10-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.